CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 27, 2006-- Elixir Licenses Exclusive U.S., Canadian and Latin American Rights from Kissei Pharmaceutical for Glufast; Product Will Enter Growing $6 Billion Diabetes Prescription Pharmaceutical Market. Elixir Pharmaceuticals, Inc. announced today that the Company has signed a definitive agreement with Kissei Pharmaceutical for the exclusive right to develop and commercialize Glufast(R) (mitiglinide calcium hydrate) in the United States, Canada, and Latin America. Currently marketed in Japan, Glufast is an insulin secretagogue that lowers post-meal glucose levels by improving the body's own ability to produce insulin. Glufast has undergone extensive clinical development demonstrating the product's ability to safely and effectively treat Type II diabetes.
